Get started
EUROPEAN MEDICAL SOLUTION NPV (POST SPLIT)EE

EUROPEAN MEDICAL SOLUTION NPV (POST SPLIT)

6.5472EURD
+0.4224+6.90%
At close at Dec 28, 2024, 03:09 GMT
EUR
No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

0RGO fundamentals

Key facts

Market capitalization‪19.89 M‬EUR
Dividend yield (indicated)—
Price to earnings Ratio (TTM)0.14
Basic EPS (TTM)0.13EUR
Founded1997
Employees (FY)—
CEOFrank Hazevoets
Websitedms-imaging.com
About

European Medical Solutions is a clinical stage biopharmaceutical company, which engages in the research and development of immunotherapy treatments for environmental and food allergies. Its products include gp-ASIT+, which is developed for the treatment of allergic rhinitis due to grass pollen; hdm-ASIT+, for the treatment of house dust mite allergy; and pnt-ASIT+for the treatment of peanut allergy. The company was founded by Thierry Legon in 1997 and is headquartered in Liege, Belgium.

Ownership
‪‪4.23 M‬‬
Free Float shares
‪‪3.85 M‬‬ (90.87%)
Closely held shares
‪‪386.40 K‬‬ (9.13%)
Free Float shares
‪‪3.85 M‬‬ (90.87%)
Closely held shares
‪‪386.40 K‬‬ (9.13%)
Capital structure
Market cap
‪‪19.89 M‬‬
Debt
‪‪19.85 M‬‬
Cash & equivalents
‪‪5.29 M‬‬
Enterprise value
‪‪34.45 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪19.89 M‬‬
Price to earning ratio (P/E)
0.14x
Price to sales ratio (P/S)
0.00x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
0.14x
Price to sales ratio (P/S)
0.00x
Valuation ratios
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪12.00‬
‪24.00‬
‪36.00‬
‪48.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−10.5%‬
‪−7.0%‬
‪−3.5%‬
‪0.0%‬
‪3.5%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬
‪‪16.00 M‬‬
‪‪24.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪6.00 M‬‬
‪‪12.00 M‬‬
‪‪18.00 M‬‬
‪‪24.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪6.00 M‬‬
‪‪12.00 M‬‬
‪‪18.00 M‬‬
‪‪24.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Medical Imaging Equipment (Radiology and Bone Densitometry)
By country
Period: 2024
Europe
North and South America
Asia
Africa
Middle East
Commonwealth of Independent States
Oceania

Dividends

Dividend yield, history and sustainability

No dividends
0RGO has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬
‪‪14.00 M‬‬
‪‪21.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪9.00 M‬‬
‪‪18.00 M‬‬
‪‪27.00 M‬‬
‪‪36.00 M‬‬
Assets
Liabilities